Current Developments in Pharmacogenomics of Multiple Sclerosis

被引：5

作者：

Carlson, Rebecca J. ^{[1
,2
]}

Doucette, J. Ronald ^{[2
,3
,4
]}

Nazarali, Adil J. ^{[1
,4
,5
]}

机构：

[1] Univ Saskatchewan, Coll Pharm & Nutr, Mol Cell Biol Lab, Saskatoon, SK S7N 5C9, Canada

[2] Univ Saskatchewan, Neurosci Res Grp, Saskatoon, SK S7N 5C9, Canada

[3] Univ Saskatchewan, Dept Anat & Cell Biol, Coll Med, Saskatoon, SK S7N 5C9, Canada

[4] City Hosp, Cameco Multiple Sclerosis Neurosci Res Ctr, Saskatoon, SK, Canada

[5] Univ Saskatchewan, Neurosci Res Grp, Saskatoon, SK S7N 5E2, Canada

来源：

CELLULAR AND MOLECULAR NEUROBIOLOGY | 2014年 / 34卷 / 08期

基金：

加拿大健康研究院;

关键词：

Pharmacogenomics; Multiple sclerosis; Interferon-beta; Glatiramer acetate; SNPs; Genome-wide association studies; INTERFERON-BETA THERAPY; GLATIRAMER ACETATE; GENE; SUSCEPTIBILITY; POLYMORPHISMS; MARKERS;

D O I：

10.1007/s10571-014-0095-0

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Pharmacogenomics has a significant potential to impact how we treat diseases. It involves targeting genetically identifiable populations with therapeutic interventions that promises to yield immediate positive health outcomes with lower or no side effects. The 'trial and error' method of treatment will no longer be necessary with the successful implementation of personalized medicine. The following is an overview of some new developments in pharmacogenomics of multiple sclerosis, and how it has the potential to improve future treatment.

引用

页码：1081 / 1085

页数：5

共 17 条

[1]

[Anonymous], MULT SCLER NAT CLIN

[2] Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis [J].

Baranzini, Sergio E. ;

Wang, Joanne ;

Gibson, Rachel A. ;

Galwey, Nicholas ;

Naegelin, Yvonne ;

Barkhof, Frederik ;

Radue, Ernst-Wilhelm ;

Lindberg, Raija L. P. ;

Uitdehaag, Bernard M. G. ;

Johnson, Michael R. ;

Angelakopoulou, Aspasia ;

Hall, Leslie ;

Richardson, Jill C. ;

Prinjha, Rab K. ;

Gass, Achim ;

Geurts, Jeroen J. G. ;

Kragt, Jolijn ;

Sombekke, Madeleine ;

Vrenken, Hugo ;

Qualley, Pamela ;

Lincoln, Robin R. ;

Gomez, Refujia ;

Caillier, Stacy J. ;

George, Michaela F. ;

Mousavi, Hourieh ;

Guerrero, Rosa ;

Okuda, Darin T. ;

Cree, Bruce A. C. ;

Green, Ari J. ;

Waubant, Emmanuelle ;

Goodin, Douglas S. ;

Pelletier, Daniel ;

Matthews, Paul M. ;

Hauser, Stephen L. ;

Kappos, Ludwig ;

Polman, Chris H. ;

Oksenberg, Jorge R. .

HUMAN MOLECULAR GENETICS, 2009, 18 (04) :767-778

[3] HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course [J].

Barcellos, LF ;

Oksenberg, JR ;

Begovich, AB ;

Martin, ER ;

Schmidt, S ;

Vittinghoff, E ;

Goodin, DS ;

Pelletier, D ;

Lincoln, RR ;

Bucher, P ;

Swerdlin, A ;

Perick-Vance, MA ;

Haines, JL ;

Hauser, SL .

AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (03) :710-716

[4] Genome-wide pharmacogenomic analysis of the response to interferon β therapy in multiple sclerosis [J].

Byun, Esther ;

Caillier, Stacy J. ;

Montalban, Xavier ;

Villoslada, Pablo ;

Fernandez, Oscar ;

Brassat, David ;

Comabella, Manuel ;

Wang, Joanne ;

Barcellos, Lisa F. ;

Baranzini, Sergio E. ;

Oksenberg, Jorge R. .

ARCHIVES OF NEUROLOGY, 2008, 65 (03) :337-E2

[5] Glypican 5 is an interferon-beta response gene: a replication study [J].

Cenit, M. D. C. ;

Blanco-Kelly, F. ;

de las Heras, V. ;

Bartolome, M. ;

de la Concha, E. G. ;

Urcelay, E. ;

Arroyo, R. ;

Martinez, A. .

MULTIPLE SCLEROSIS JOURNAL, 2009, 15 (08) :913-917

[6]

Comabella M, 2009, ARCH NEUROL-CHICAGO, V66, P972, DOI 10.1001/archneurol.2009.150

[7] ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis [J].

Cotte, S. ;

von Ahsen, N. ;

Kruse, N. ;

Huber, B. ;

Winkelmann, A. ;

Zettl, U. K. ;

Starck, M. ;

Koenig, N. ;

Tellez, N. ;

Doerr, J. ;

Paul, F. ;

Zipp, F. ;

Luehder, F. ;

Koepsell, H. ;

Pannek, H. ;

Montalban, X. ;

Gold, R. ;

Chan, A. .

BRAIN, 2009, 132 :2517-2530

[8] HLA DR and DQ alleles and haplotypes associated with clinical response to glatiramer acetate in multiple sclerosis [J].

Dhib-Jalbuta, Suhayl ;

Valenzuela, Reuben M. ;

Ito, Kouichi ;

Kaufman, Michael ;

Picone, Mary Ann ;

Buyske, Steve .

MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2013, 2 (04) :340-348

[9] HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis [J].

Fusco, C ;

Andreone, V ;

Cappola, G ;

Luongo, V ;

Guerini, F ;

Pace, E ;

Florio, C ;

Pirozzi, G ;

Lanzillo, R ;

Ferrante, P ;

Vivo, P ;

Mini, M ;

Macrì, M ;

Orefice, G ;

Lombardi, ML .

NEUROLOGY, 2001, 57 (11) :1976-1979

[10] Population structure and HLA DRB1*1501 in the response of subjects with multiple sclerosis to first-line treatments [J].

Gross, Robert ;

Healy, Brian C. ;

Cepok, Sabine ;

Chitnis, Tanuja ;

Khoury, Samia J. ;

Hemmer, Bernard ;

Weiner, Howard L. ;

Hafler, David A. ;

De Jager, Philip L. .

JOURNAL OF NEUROIMMUNOLOGY, 2011, 233 (1-2) :168-174

← 1 2 →